Intismeran Clinical Trials

1 actively recruiting trial across 1 location

Also known as: V940, mRNA-4157

Pipeline

Phase 3: 1

Top Sponsors

Merck Sharp & Dohme LLC1

Indications

Lung Cancer1
Non Small Cell Lung Cancer1
Cancer1

Lincoln, Nebraska1 trial

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

NHO Revive Research Institute, LLC ( Site 3218)

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.